Press "esc" to clear
Go to Advanced Search

Showing results

110 of 311
Mayumi.Fujita.2.jpg

Article ID: 702110

Cancer Stem Cells Use “Normal” Genes in Abnormal Ways

University of Colorado Cancer Center

University of Colorado Cancer Center study shows that "normal" gene CDK1 interacts with "abnormal" gene Sox2 to keep cancer stem cells "stemmy."

Released:
12-Oct-2018 8:05 AM EDT
News.Craig.Jordan.jpg

Article ID: 701304

Cancer Hijacks the Microbiome to Glut Itself on Glucose

University of Colorado Cancer Center

A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.

Released:
28-Sep-2018 11:05 AM EDT

Article ID: 701045

Making old antibiotics new again

University of Colorado Boulder

CU Boulder researchers have identified a family of small molecules that turn off defense mechanisms inside bacteria that enable them to resist antibiotics. The compounds could ultimately be given alongside existing medications to rejuvenate them.

Released:
26-Sep-2018 3:05 AM EDT
Bob.Doebele.2018.iv.jpg
  • Embargo expired:
    24-Sep-2018 9:45 AM EDT

Article ID: 700973

Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer

University of Colorado Cancer Center

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

Released:
24-Sep-2018 8:45 AM EDT
News.Craig.Jordan.jpg

Article ID: 700416

New Combination Treatment Targets Pre-Leukemia Stem Cells

University of Colorado Cancer Center

Omacetaxine (to block protein synthesis) with venetoclax (to block oxidative phosphorylation), was highly effective against CD123+ leukemia stem cells.

Released:
12-Sep-2018 1:05 PM EDT

Showing results

110 of 311

Chat now!